

Blue Owl

2Q23 Results Largely in Line, Fundraising Softer, Broad Credit Centric Opportunity Remains, Dyal Questions Resolved

Blue Owl reported 2Q23 Adj. EPS of \$0.16, matching both our and Bloomberg consensus estimates. Fee-related Adj. EPS of \$0.17 were also in line with estimates, in what proved to be a relatively uneventful quarter from a summary financials perspective. The story on the call was substantially more interesting, however, with Owl effectively taking the GP Strategic Capital (fka Dyal Capital) overhang off the table by putting forth a strong long-term incentive alignment with business founder (and current overall Blue Owl co-president) Michael Rees. Total fundraising came in softer than expected, but we don't necessarily see a major cause for concern on that front as the private wealth channel saw a step up QoQ (from \$1.6bn to \$1.8bn) and management has consistently messaged that the institutional side of the house tends to be episodic (substantial SMA / bespoke structure activity). Management highlighted the resiliency and differentiation of the overall Blue Owl platform (we agree) across Direct Lending, GP Capital Solutions, and Real Estate, and pointed to double-digit returns of the last 12 months for Credit (18.9%) and Real Estate (14.2%) as a positive contrast to volatile markets over the same period. Further to resolving questions around the reported on internal constituent uncertainty, OWL focused on presenting a united message, which included a re-brand of the various legacy businesses under the Blue Owl name, and an outline towards continuing to build capabilities towards being a broader provider of capital markets solutions.

- Reviewing the print. Blue owl reported fee-related earnings of \$245mm (+24% YoY), in line with our projections and just a hair above the \$244mm consensus. Total adjusted revenues of \$401mm topped consensus of \$396mm and presented 6% QoQ and 26% YoY growth. The direct lending business continued to be the largest contributor of the top line (58%), followed by GP Capital (35%), and Real Estate (8%). We note that Part I fees were particularly strong this quarter, with the \$91mm actuals topping our estimates by \$5mm and presenting 100% YoY growth – a positive indicator for the continued growth and healthy operating environment of the BDC franchise. Though total expenses moved higher both on a yearly (+26%) and quarterly (+2%) basis, FRE margins stepped up to 61%, following two consecutive quarters of hovering around 60%. The margin expansion was in part driven by a stronger quarter with regard to administrative, transaction and other fees (\$20mm in 2Q23 vs. \$9mm in 1Q23), in what was the best quarter for this line item since 2Q22 (\$25mm). We also note that OWL continued to enjoy industry-leading blended fee rates, with 2Q23's average rate of 1.65% increasing modestly from 1Q23's 1.63%.
- Deployment shows signs of improvement. We were pleased to see Blue Owl's direct lending gross originations take a step up quarter over quarter (from \$1.6bn in 1Q23 to \$3.4bn in 2Q23), though we note that the figure was still

Neutral

OWL, OWL US Price (02 Aug 23):\$12.33 Price Target (Dec-23):\$13.00

Brokers, Asset Managers & Exchanges

Kenneth B. Worthington, CFA AC

(1-212) 622-6613

kenneth.b.worthington@jpmorgan.com

Bloomberg JPMA WORTHINGTON <GO>

Michael Cho

(1-212) 622-3619 michael.cho@jpmchase.com

Alexander Bernstein

(1-212) 622 0369

alexander.x.bernstein@jpmorgan.com

Madeline Daleiden

(1-212) 622-4911

madeline.daleiden@jpmchase.com J.P. Morgan Securities LLC

Quarterly Forecasts (FYE Dec)							
Adj. EPS (\$)							
	2022A	2023E	2024E				
Q1	0.11	0.15A	0.17				
Q2	0.13	0.16A	0.18				
Q3	0.14	0.16	0.19				
Q4	0.15	0.17	0.21				
FY	0.53	0.64	0.75				

Style Exposure


Quant	Current	k (1=To	<u>p)</u>		
Factors	%Rank	6M	1Y	3Y	5Y
Value	93	79	96		
Growth	82				
Momentum	41	77	9		
Quality	82	98	93	85	100
Low Vol	83	87	87		

Sources for: Style Exposure - J.P. Morgan Quantitative and Derivatives Strategy; all other tables are company data and J.P. Morgan estimates.

See page 7 for analyst certification and important disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.





Company Data	
Shares O/S (mn)	1,415,459
52-week range (\$)	14.04-8.06
Market cap (\$ mn)	17,452,600.00
Exchange rate	1.00
Free float(%)	99.9%
3M - Avg daily vol (mn)	3.37
3M - Avg daily val (\$ mn)	37.3
Volatility (90 Day)	30
Index	S&P 500
BBG BUY HOLD SELL	10 2 0

Key Metrics (FYE Dec)			
\$ in millions	FY22A	FY23E	FY24E
Financial Estimates			
Investment advisory/ Mgt. Fees	1,249	1,535	1,805
Performance fees	-	-	-
Total revenue	1,322	1,603	1,898
Compensation and benefits	(361)	(450)	(519)
Operating expense	-	-	-
Adj. EBIT	792	975	1,160
Adj. PBT	752	923	1,114
Adj. net income	743	905	1,067
Adj. EPS	0.53	0.64	0.75
BBG EPS	0.53	0.65	0.82
DPS	-	-	-
Total AUM	138	160	-
Net flows	32	15	-
Margins and Growth			
EBIT margin	60.0%	60.8%	61.1%
Adj. EPS growth	66.0%	20.5%	16.7%
AUM growth	-	-	-
Ratios			
Adj. tax rate	1.3%	1.9%	4.2%
Net flows/Opening AUM	-	-	-
Revenues/Avg. AUM (bps)	-		-
RoAUM (bps)	63,842.8	60,709.8	-
ROCE	0.0%	0.0%	0.0%
Valuation			
Dividend yield	-	-	-
EV/AUM	13703509.4%		-
Adj. P/E	23.2	19.3	16.5


Summary Investment Thesis and Valuation

Investment Thesis

Blue Owl is a leading alternative investment manager across its three key business lines: Owl Rock (direct lending), Dyal (general partner/GP solutions), and Oak Street (triple net lease real estate). We believe Blue Owl has ample capacity to organically grow its AUM (and FPAUM) over the medium term, but we acknowledge that Blue Owl's business is tied to the success of broader alternative investment management firms as well. While Blue Owl's attractive investment products and medium-term outlook remain solid, we acknowledge Blue Owl is already trading at a premium valuation to peers, and the current market uncertainty around macro/credit creates a near-term headwind to Blue Owl's stock.

Valuation

We value Blue Owl on a sum-of-the-parts basis attributing a 24x multiple to the fee-related earnings and a 10% discount on cash and investments. Unique to Blue Owl's structure, we do not forecast any performance fees. Our Blue Owl Dec-23 price target is \$13.




Factors	6M Corr	1Y Corr	
Market: MSCI US	0.70	0.73	
Sect: Financials	0.34	0.28	
Ind: Diversified Fin	0.58	0.46	
Macro:			
Non-Energy Commodity	0.45	0.32	
US Dollar	-0.47	-0.32	
Credit Spread	-0.22	-0.13	
Quant Styles:			
Momentum	-0.56	-0.54	
Size	-0.40	-0.42	
LowVol	-0.36	-0.40	



relatively muted on a YoY basis relative to 2Q22 (\$7.6bn). In discussing the direct lending opportunity, management noted that today's markets are seeing very limited refinancing activity (in contrast to when 20-25% of OWL's loans used to get refinanced when rates were low and M&A deal-making was active), and hence most of the dollars that Blue Owl is putting to work are reflective of new capital moving in (i.e., less capacity being created by refinancing so less capital sitting on the sidelines than the headline numbers would suggest). As we have heard from a number of other management teams, OWL noted that private credit markets do move in tandem with M&A markets, and thus the moderate pickup being experienced on the M&A side currently is helpful, though too early to draw any substantive conclusions about. Management also pointed out that Blue Owl enjoys differentiation in the market place as an "independent" partner to financial sponsors, given many of the other large direct lenders in the market are part of broader private equity franchises that may compete with the same sponsors on deals – we buy this.

- Credit quality remains healthy. Similar to some of the commentary provided by Ares on its earnings call (our note here), OWL was able to effectively assuage potential concerns about credit quality, noting that portfolio companies in its lending book continued to see healthy Revenue and EBITDA growth, without any substantial changes to non-accruals or step-ups in amendment requests. Weighted average LTVs in the 40s for the whole portfolio and in the 30s for the tech-dedicated portfolio also screen as healthy. Blue Owl also pointed out that annualized realized losses on the \$78bn of loans originated since inception have been just ~6bps.
- Fundraising comes in light, but not much cause for concern. OWL's total 2Q23 capital commitments of \$2.9bn came in below our \$4.4bn estimates, and took a step down from 1Q23's \$3.8bn. As we noted above, while the private wealth channel saw a ~\$200mm QoQ increase, the institutional side of the house slowed with actuals of \$1.1bn halving from last quarter. With management reiterating on the earnings call expectations that 2023 fundraising will likely lean institutional (currently \$3.3bn institutional vs. \$3.4bn retail in H1 with private wealth momentum looking strong), we continue to expect a pickup in institutional fundraising in the back half of the year. In terms of where this fundraising may come from, management noted that flagship real estate fund VI is still in market and expressed confidence in hitting the \$5bn marker that would double the size of fund V. With GP stakes fund V more than 75% invested, management noted that a Fund VI fundraise is on the horizon, and there exists some potential that the base case of a first close in early next year could conceivably be brought in earlier. Although OWL has achieved substantial growth since the May 2022 investor day, when 2023 goals were outlined, management did concede that targets to achieve \$1bn of distributable earnings and \$50bn in fee-paying AUM in 2023 were currently tracking about a quarter behind the initial outline.
- GP Stakes business overhang removed. As we outlined in our earnings preview note (here), a number of news periodicals including Bloomberg had been reporting over the past few months that OWL may be experiencing internal strife between the historical Owl Rock and Dyal sides of the house. Those concerns were confidently assuaged on yesterday's earnings call when Dyal founder Michael Rees outlined his long-term commitment to the Blue Owl franchise and noted that he has elected to receive 100% of his compensation for the following 3 years via OWL equity. Given the substantial news flow around this topic, we expect this resolution to be quite helpful for overall sentiment around the GP Capital solutions segment of the business and potential fundraising prospects.
- Excitement about real estate. The real estate segment enjoyed the largest QoQ revenue growth (+17%) of the three OWL operating segments, in line with bullish management commentary around the opportunity set. Blue Owl expressed optimism around the net lease product's effective positioning against the backdrop of elevated borrowing costs and more constrained financing markets, noting a robust pipeline with ~\$3.8bn of near-





term transaction volume under letter of intent or contract to close. With OWL already deploying out of the currently \$3.7bn Fund VI (expected to hit the \$5bn hard cap), the strategy appears to be in the midst of a rapid fundraise -> deploy -> realize virtuous cycle. We also note expectations of further upside on the private wealth side as management confirmed the onboarding of a wire-house partner for the perpetual RE product in 2Q23 and expectations of expanding the syndicate further through 2024. At the end of the day, strong returns drive strong fundraising, and with the real estate segment generating 2.3% returns in 2Q23 and 14.2% returns over the past 12 months, OWL's product likely will continue to screen as differentiated to investors.

• Maintain our Neutral rating and our \$13 Dec 2023 price target. On the net, the changes we make to our model do not alter our FY 2023 Adj. EPS projection of \$0.64 or our FY 2024 Adj. EPS projection of \$0.75. We continue to apply a 24x multiple to OWL fee-related earnings, and move from a 15% to a 10% discount on cash and investments, more consistent with the discount we apply to peer investment portfolios.



Investment Thesis, Valuation and Risks

Blue Owl (Neutral; Price Target: \$13.00)

Investment Thesis

Blue Owl is a leading alternative investment manager across its three key business lines: Owl Rock (direct lending), Dyal (general partner/GP solutions), and Oak Street (triple net lease real estate). We believe Blue Owl has ample capacity to organically grow its AUM (and FPAUM) over the medium term, but we acknowledge that Blue Owl's business is tied to the success of broader alternative investment management firms as well. While Blue Owl's attractive investment products and medium-term outlook remain solid, we acknowledge Blue Owl is already trading at a premium valuation to peers, and the current market uncertainty around macro/credit creates a near-term headwind to Blue Owl's stock.

Valuation

We value Blue Owl on a sum-of-the-parts basis attributing a 24x multiple to the fee-related earnings and a 10% discount on cash and investments. The 24x multiple is a premium to peers and is justified by the large portion of Blue Owl earnings related to permanent capital vehicles. Unique to Blue Owl's structure, we do not forecast any performance fees. We maintain our Dec-23 price target at \$13.

Risks to Rating and Price Target

Blue Owl is an alternative asset manager dependent on the success of the alternative asset management business

Blue Owl is a multifaceted and multilayered play on the success of the alternative asset management ecosystem and the outlook for deal making over the near term and longer term. The alternative asset management industry has been in exuberant market conditions for many years. But continued weakness in growth investing and a slowdown in deal making could slow industry deployment and therefore slow Blue Owl's ability to make loans and deploy BDC capital.

Macroeconomic and credit market risk

To date, Blue Owl has demonstrated the ability to be highly selective in its investments and has delivered solid returns to its investors. That said, the US has been in a bull market for over 10 years and Blue Owl has not experienced a full economic cycle (ex-COVID) as a combined business. If rates rise more than expected, Blue Owl earnings could be better than forecast and the stock could outperform. However, if the credit environment deteriorates, the stock could underperform.

Performance could deteriorate, impacting future fundraising efforts

Blue Owl's performance track record since inception has been solid across its key strategies. That said, any underperformance could impact future fundraising efforts.



Blue Owl: Summary of Financials

Income Statement - Annual	FY22A	FY23E	FY24E	FY25E	Income Statement - Quarterly	1Q23A	2Q23A	3Q23E	4Q23E
Management Fees	1,249	1,535	1,805	_	Management Fees	369A	382A	387	397
Portfolio Advisory Fees, net		-,	-	_	Portfolio Advisory Fees, net	-	-	-	-
Transaction Fees, net	73	68	93	_	Transaction Fees, net	9A	20A	18	22
Performance Fee Income	-	-	-	-	Performance Fee Income	-	-	-	-
Investment Income	-	-	-	-	Investment Income	-	-	-	-
Interest and Other Income	0	0	0	-	Interest and Other Income	0A	0A	0	0
Total Revenues	1,322	1,603	1,898	-	Total Revenues	377A	401A	405	419
Compensation and Benefits	(361)	(450)	(519)	-	Compensation and Benefits	(104)A	(116)A	(113)	(117)
Performance Fee Compensation	-	-	-	-	Performance Fee Compensation	-	-	-	-
G&A	(168)	(178)	(218)	-	G&A	(48)A	(39)A	(45)	(46)
Interest Expense	-	-	-	-	Interest Expense	(14)A	(14)A	(14)	(14)
Total expenses	(474)	(573)	(685)	-	Total expenses	(138)A	(141)A	(144)	(150)
Distributable Earnings (DE)	743	905	1,067	-	Distributable Earnings (DE)	209A	227A	230	239
DE/Share	0.53	0.64	0.75	-	DE/Share	0.15A	0.16A	0.16	0.17
Balance Sheet and Cash Flow Data	FY22A	FY23E	FY24E	FY25E	Ratio Analysis	FY22A	FY23E	FY24E	FY25E
Cash & Cash Equivalents	68,079	203,186	536.531	_	EPS growth	66.0%	20.5%	16.7%	_
Intangible Assets, net	2,405,422	2,405,422	,	_	Operating margin	79.6%	23.0%	19.0%	_
Total assets	8,575,844	8,710,951	, ,	_	- paraming mangin				
	, ,				Tax rate	1.3%	1.9%	4.2%	-
Loans Payable	-	-	-	-	Net income margin	56.2%	56.5%	56.2%	-
Account Payable	126,559	126,559	126,559	-	-				
Loans Payable of Consolidated Funds	1,624,771	1,624,771	1,624,771	-	AUM growth	-	-	-	-
					AUM growth from market	-	-	-	-
Total liabilities	3,344,189	3,344,189	3,344,189	-	AUM growth from sales	-	-	-	-
Total Equity	5,231,655	5,366,762	5,700,107	-	Average fee rate	-	_	-	-
Total liabilities & equity	8,575,844	8,710,951	9,044,296	-					
					Return on equity (ROE)	0.0%	0.0%	0.0%	-
					Dividends	_	_	_	_
					Dividorido				

Source: Company reports and J.P. Morgan estimates.

Note: \$ in millions (except per-share data). Fiscal year ends Dec




Analyst Certification: The Research Analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst's personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst's analysis was made in good faith and that the views reflect the Research Analyst's own opinion, without undue influence or intervention.

All authors named within this report are Research Analysts who produce independent research unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.

Important Disclosures

- Market Maker/ Liquidity Provider: J.P. Morgan is a market maker and/or liquidity provider in the financial instruments of/related to Blue Owl.
- Client: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients: Blue Owl.
- Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-investment-banking, securities-related: Blue Owl.
- Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-securities-related: Blue Owl.
- Non-Investment Banking Compensation Received: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Blue Owl.
- Debt Position: J.P. Morgan may hold a position in the debt securities of Blue Owl, if any.

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan—covered companies, and certain non-covered companies, by visiting https://www.jpmm.com/research/disclosures, calling 1-800-477-0406, or e-mailing research.disclosure.inquiries@jpmorgan.com with your request.



Source: Bloomberg Finance L.P. and J.P. Morgan; price data adjusted for stock splits and dividends. Initiated coverage Jul 07, 2022. All share prices are as of market close on the previous business day.

The chart(s) show J.P. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period. J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Neutral [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Not Rated (NR): J.P. Morgan has removed the rating and, if applicable, the price target, for this stock



because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap equity research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those analysts' coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying analyst's coverage universe can be found on J.P. Morgan's research website, https://www.jpmorganmarkets.com.

Coverage Universe: Worthington, Kenneth B: Apollo Global Management Inc (APO), Ares Management (ARES), BlackRock (BLK), Blackstone (BX), Blue Owl (OWL), Bridge Investment Group (BRDG), Brookfield Asset Management (BAM), Brookfield Corporation (BN), CME Group Inc. (CME), Carlyle Group Inc./The (CG), Cboe Global Markets (CBOE), Charles Schwab (SCHW), Coinbase (COIN), Federated Hermes (FHI), Forge Global (FRGE), Franklin Resources (BEN), GCM Grosvenor (GCMG), Hamilton Lane (HLNE), Houlihan Lokey (HLI), Invesco Ltd. (IVZ), Janus Henderson (JHG), Janus Henderson Group plc (JHG.AX), Moelis (MC), P10 (PX), Robinhood (HOOD), StepStone (STEP), T. Rowe Price Group, Inc (TROW), TPG Inc. (TPG), The Intercontinental Exchange (ICE), Tradeweb (TW), Victory Capital (VCTR), Virtu Financial (VIRT)

J.P. Morgan Equity Research Ratings Distribution, as of July 08, 2023

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage*	47%	39%	14%
IB clients**	48%	45%	34%
JPMS Equity Research Coverage*	45%	42%	12%
IB clients**	67%	64%	53%

*Please note that the percentages may not add to 100% because of rounding.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at http://www.jpmorganmarkets.com, contact the primary analyst or your J.P. Morgan representative, or email research.disclosure.inquiries@jpmorgan.com. For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, http://www.jpmorganmarkets.com. This report also sets out within it the material underlying assumptions used.

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of http://www.ipmorganmarkets.com where you can also search by analyst name, sector or financial instrument.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

UK MIFID FICC research unbundling exemption: UK clients should refer to <u>UK MIFID Research Unbundling exemption</u> for details of JPMorgan's implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

Any digital or crypto assets discussed in this research report are subject to a rapidly changing regulatory landscape. For relevant regulatory advisories on crypto assets, including bitcoin and ether, please see https://www.jpmorgan.com/disclosures/cryptoasset-disclosure.

^{**}Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.



The author(s) of this research report may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so.

Exchange-Traded Funds (ETFs): J.P. Morgan Securities LLC ("JPMS") acts as authorized participant for substantially all U.S.-listed ETFs. To the extent that any ETFs are mentioned in this report, JPMS may earn commissions and transaction-based compensation in connection with the distribution of those ETF shares and may earn fees for performing other trade-related services, such as securities lending to short sellers of the ETF shares. JPMS may also perform services for the ETFs themselves, including acting as a broker or dealer to the ETFs. In addition, affiliates of JPMS may perform services for the ETFs, including trust, custodial, administration, lending, index calculation and/or maintenance and other services.

Options and Futures related research: If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit https://www.theocc.com/components/docs/riskstoc.pdf for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or https://www.finra.org/sites/default/files/Security_Futures_Risk_Disclosure_Statement_2018.pdf for a copy of the Security Futures Risk Disclosure Statement.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: https://www.ipmorgan.com/global/disclosures/interbank offered rates

Private Bank Clients: Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries ("J.P. Morgan Private Bank"), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

Legal entity responsible for the production and distribution of research: The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below, this material has been distributed by the legal entity responsible for production. If you have any queries, please contact the relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

Legal Entities Disclosures and Country-/Region-Specific Disclosures:

Argentina: JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina ("BCRA"- Central Bank of Argentina) and Comisión Nacional de Valores ("CNV"- Argentinian Securities Commission" - ALYC y AN Integral N°51). Australia: J.P. Morgan Securities Australia Limited ("JPMSAL") (ABN 61 003 245 234/AFS Licence No. 238066) is regulated by the Australian Securities and Investments Commission and is a Market, Clearing and Settlement Participant of ASX Limited and CHI-X. This material is issued and distributed in Australia by or on behalf of JPMSAL only to "wholesale clients" (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting https://www.jpmm.com/research/disclosures. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia's Research Independence Policy which can be found at the following link: <u>J.P. Morgan Australia - Research Independence Policy</u>. **Brazil**: Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / ouvidoria.jp.morgan@jpmorgan.com. Canada: J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Investment Industry Regulatory Organization of Canada and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P.Morgan Securities Canada Inc. Chile: Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile. China: J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business. Dubai International Financial Centre (DIFC): JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by JP Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules. European Economic Area (EEA): Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan SE ("JPM SE"), which is subject to prudential supervision by the European Central Bank ("ECB") in cooperation with BaFin and Deutsche Bundesbank in Germany. JPM SE is a company headquartered in Frankfurt with registered address at TaunusTurm, Taunustor 1, Frankfurt am Main, 60310, Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions ("EEA professional investors"). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong Branch (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. Where the distribution of this material is a regulated



activity in Hong Kong, the material is distributed in Hong Kong by or through J.P. Morgan Securities (Asia Pacific) Limited and/or J.P. Morgan Broking (Hong Kong) Limited. India: J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is registered with the Securities and Exchange Board of India (SEBI) as a 'Research Analyst' having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: http://www.jpmipl.com. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL: IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Compliance Officer: Spurthi Gadamsetty; spurthi.gadamsetty@jpmchase.com; +912261573225. Grievance Officer: Ramprasadh K, jpmipl.research.feedback@jpmorgan.com; +912261573000.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Indonesia: PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is registered and supervised by the Otoritas Jasa Keuangan (OJK). Korea: J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch. Japan: JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan. Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia. Mexico: J.P. Morgan Casa de Bolsa, S.A. de C.V. and J.P. Morgan Grupo Financiero are members of the Mexican Stock Exchange and are authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. New Zealand: This material is issued and distributed by JPMSAL in New Zealand only to "wholesale clients" (as defined in the Financial Markets Conduct Act 2013). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008. Pakistan: J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan. Philippines: J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. Russia: CB J.P. Morgan Bank International LLC is regulated by the Central Bank of Russia. Singapore: This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MCI (P) 060/08/2022 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore), both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material. As at the date of this material, JPMSS is a designated market maker for certain structured warrants listed on the Singapore Exchange where the underlying securities may be the securities discussed in this material. Arising from its role as a designated market maker for such structured warrants, JPMSS may conduct hedging activities in respect of such underlying securities and hold or have an interest in such underlying securities as a result. The updated list of structured warrants for which JPMSS acts as designated market maker may be found on the website of the Singapore Exchange Limited: http://www.sgx.com. South Africa: J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Board. Taiwan: J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material. Thailand: This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission, and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500. UK: Unless specified to the contrary, research is distributed in the UK by J.P. Morgan Securities plc ("JPMS plc") which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. JPMS plc is registered in England & Wales No. 2711006, Registered Office 25 Bank Street, London, E14 5JP. This material is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 ("the FPO"); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as "UK relevant persons". This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. Research issued by



JPMS plc has been prepared in accordance with JPMS plc's policy for prevention and avoidance of conflicts of interest related to the production of Research which can be found at the following link: J.P. Morgan EMEA - Research Independence Policy. U.S.: J.P. Morgan Securities LLC ("JPMS") is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is distributed in the U.S. by JPMS who accepts responsibility for its content.

General: Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject company(ies) that may be discussed in the material. J.P. Morgan accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

Confidentiality and Security Notice: This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. This message is subject to electronic monitoring: https://www.jpmorgan.com/disclosures/email

MSCI: Certain information herein ("Information") is reproduced by permission of MSCI Inc., its affiliates and information providers ("MSCI") ©2023. No reproduction or dissemination of the Information is permitted without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES (INCLUDING MERCHANTABILITY OR FITNESS) AS TO THE INFORMATION AND DISCLAIMS ALL LIABILITY TO THE EXTENT PERMITTED BY LAW. No Information constitutes investment advice, except for any applicable Information from MSCI ESG Research. Subject also to msci.com/disclaimer

"Other Disclosures" last revised July 08, 2023.

Copyright 2023 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.

Completed 03 Aug 2023 03:20 PM EDT

Disseminated 03 Aug 2023 03:20 PM EDT